Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EPS (Weighted Average and Diluted) (2023 - 2025)

Tonix Pharmaceuticals Holding has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$4.15 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$4.15 for Q4 2025, down 101.43% from a year ago — trailing twelve months through Dec 2025 was -$14.44 (up 99.34% YoY), and the annual figure for FY2025 was -$14.57, up 91.75%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$4.15 at Tonix Pharmaceuticals Holding, down from -$3.59 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TNXP hit a ceiling of $289.57 in Q4 2024 and a floor of -$14576.8 in Q4 2023.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$13.42 (2025), compared with a mean of -$1406.0.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 101.99% in 2024, while the deepest fall reached 16589.1% in 2024.
  • Tonix Pharmaceuticals Holding's EPS (Weighted Average and Diluted) stood at -$14576.8 in 2023, then soared by 101.99% to $289.57 in 2024, then tumbled by 101.43% to -$4.15 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$4.15 (Q4 2025), -$3.59 (Q3 2025), and -$3.86 (Q2 2025) per Business Quant data.